You are here
Focus on the european MiMédi project
On Tuesday 11 June 2019, the teams of the FEMTO-ST Institute and the EFS Bourgogne-Franche-Comté will present, in the presence of representatives of the regional district, an important European research project on regional smart specialisation. Bringing together 10 industrial and academic partners, it aims to optimize the manufacture of "drug cells" through new technological solutions.
Innovative medicines (Medi) have recently emerged to offer new treatment solutions for patients in therapeutic impasse. These "Medi" are based on the use of "drug cells" with new physiological functions, biological characteristics or reconstitutional properties inspired by the body's natural processes, but the manufacture of these drugs requires the use of complex technologies for cell sorting, amplification, genetic transduction, amplification-division, activation, at several stages of production and all this in a controlled clean room environment. Given these different manufacturing constraints, their production is therefore expensive. This is why a new conception of the current mode of production and qualification of the Medias is necessary.
This is the subject of the FEDER MiMédi project - Microtechniques pour les Médicaments Innovants - of smart specialisation (RIS3) which will make it possible to combine microtechnical skills with those of the production of tomorrow's medicines, paving the way for a promising future sector in the Region. These developments should ultimately facilitate the marketing of innovative medicines to combat public health problems such as cancer, inflammation and tissue repair.
This 4-year project, with a total budget of €13.6 million, is financed to the tune of €10.2 million by ERDF funds, €584,000 by the Regional Innovation Fund (RIF) and €2.8 million in self-financing. It is supported by ILSA and involves 5 other industrial partners, a transfer centre and 3 academic partners, including the University of Franche-Comté via FEMTO-ST.
